Bayer AG Halts Sales of Trasylol. Read More on Our News and Events Page.
Trasylol (an aprotinin injection) is a drug approved to decrease blood loss during cardiopulmonary bypass surgery. This reduces the possible need for blood transfusion in patients undergoing heart surgery.
Studies Find Trasylol Linked to Increased Risk of Kidney Failure and Stroke
A study performed by the Ischemia Research and Education Foundation found that the use of Trasylol doubled the risk of kidney failure in cardiopulmonary bypass surgery patients. This study also found that a risk of heart failure more than doubled after Trasylol had been used in operation. Patients that had used Trasylol also showed an increased risk of stroke by 181%.
In 2006 the Food and Drug Administration announced that Bayer (the drugs manufacturer) had failed to reveal the results of the study linking Trasylol to stroke or possible death. Trasylol, while effective in reducing the need for transfusion, has been linked to a number of serious side-effects including:
- Allergic Reactions
- Kidney Failure
- Heart Attacks
- Stroke
FDA Public Health Advisory Regarding Trasylol
In February of 2006 the Food and Drug Administration issued a public health advisory for doctors who perform heart bypass surgery and their patients concerning the potential serious side-effects of Trasylol. Trasylol is the only drug approved by the FDA for the prevention of peri-operative blood loss and the need for blood transfusion among patients undergoing coronary artery bypass graft surgery.
Read the FDA Public Health Advisory Concerning Trasylol
An FDA Alert was issued in December of 2006 for Aprotinin Injection marketed as Trasylol. This alert covered the new prescription revisions and new labeling for the drug. This alert also warned against renal dysfunction.
Pharmaceutical Litigation Attorneys at Bailey & Galyen have extensive experience in cases involving injury or wrongful death associated with prescription drugs. Contact us to set an appointment with an attorney to discuss your case.
